Aptahem reports prepared GMP certified Apta-1 for preparation of clinical studies
Aptahem announces today that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 successfully has been prepared by the collaboration partner LGC Biotechnologies in the USA, according to timeplan. The GMP manufactured Apta-1 will be used in the future clinical studies.Aptahem’s partner LGC has improved the process parameters for the GMP production and with that obtained a more efficient CoG (Cost of Goods) which is an important part of creating an attractive partnering deal. The final delivery has met the company’s quality goals and also exceeded